about
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaVismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Phase II study of carboplatin in children with progressive low-grade gliomas.Phase II trial of temozolomide in patients with progressive low-grade glioma.Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.Temozolomide in children with progressive low-grade glioma.Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant gliomaPhase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium studyCNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity.Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium.Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyInnovations in design and delivery of chemotherapy for brain tumors.Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Chemotherapy and novel therapeutic approaches in malignant glioma.Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningiomaAmifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
P50
Q24644727-D98DB98E-64AB-4F43-8CB8-EAB02D54C1F5Q27853187-98123824-CA59-46EC-BB92-FEA660E0CA28Q30578179-572C1BCC-751C-409E-B9F8-45ED218EB52BQ33343014-7EC9EF74-D120-42C3-B3CE-0324DECE4A93Q33346531-8A180B4E-AA26-4E83-8C1C-430DB404B115Q33369628-A0AE024F-FCBB-4968-888A-F722C05DCD84Q33370229-C882117E-0B6B-4094-9200-2C0C9CBA3855Q33374472-3ED752E2-C1B9-489B-A161-48A1E2022E4AQ33377386-8DA8B3E2-A29B-49C9-918B-D9A93654BBDDQ33383721-246DB3F8-6446-4AE1-9F9D-2EC0A0DF2F90Q33384269-68F150E8-C385-4811-B5A1-C5E1107363F9Q33396181-FB0B57CE-2F8B-4C9B-AF87-DC9DE3870070Q33397569-3797BE16-06C7-48E6-B1BC-BCBC7B634A44Q33399939-CD043F60-8BCD-4E3D-9559-FF47317867C4Q33718154-ED8D2999-D842-4E50-9BB5-CB305805077CQ33747609-DAD31DB9-8387-4F78-B9CD-8B8BE2A14E26Q33990959-A20C9931-8CAE-454A-A92B-2D8C56D6A14AQ34157312-4E479110-4400-4E69-BDA4-C0D94CCFDF56Q34455197-8E951CBE-B83F-43E3-81D7-B045C9D021ECQ34480689-C896A16F-8881-4FDA-A477-1FA76F58FE43Q34610598-78CE79FF-88E1-4D19-8DC7-687849E64553Q35008709-D8A500A3-6C24-4773-BCD5-E9FDB8A34667Q35008766-412DDC42-E90C-428E-9B27-7B51E1AAB82FQ35104257-24C023DC-63F2-47B3-9C13-CBAD168FC4C6Q35172814-C211E7B1-3BB2-4514-99F7-DF87B4B22F5AQ35229738-CB404F3F-9EBD-4D62-BB43-D0B020BA126FQ35747427-DE9BB086-C115-4AE1-8024-7F8754B3381CQ35800735-DDB88744-1AE6-4B0C-83D7-0B178BD517E2Q35800752-EA01894A-6CC0-41F3-A763-08A6487B836AQ35894865-A957BB29-B26D-479D-8EEE-F448D3BE5FCBQ36103026-32D39B2B-8BBD-4541-8D22-85FF860F37EAQ36170303-91AD0FEF-BB1D-499A-BF48-87BD8728E548Q36344746-76E43E42-28CA-4486-84B3-88541505473EQ36378403-A7764723-0AC9-4597-8F31-3F8C90878EF7Q36410210-1E1BD688-D7AB-4F81-AA1D-66C9C4AF1C88Q36494268-7480A5E9-CC90-4FCC-83E6-E7884530A686Q36612342-89BF18D4-9DDE-45C5-8AFD-9C475FF69995Q36740517-1838D4A4-E3E2-4E23-9CDE-9B9A0290BFAAQ36825081-9BAF7854-AAFE-4848-986A-0D2EE84B6508Q36900428-D0399F48-4B53-4F70-BABD-A8AD5A4216E5
P50
name
Sridharan Gururangan
@en
Sridharan Gururangan
@nl
type
label
Sridharan Gururangan
@en
Sridharan Gururangan
@nl
prefLabel
Sridharan Gururangan
@en
Sridharan Gururangan
@nl